Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of September 15, 2026, ATNM trades at $1.29 with a market cap of $44.02M and a P/E ratio of 3.49. ATNM moved +0.39% today. Year to date, ATNM is -5.88%; over the trailing twelve months it is -21.47%. Its 52-week range spans $0.74 to $2.41. Analyst consensus is moderatebuy with an average price target of $3.50. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ATNM, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $1.29 |
| Market Cap | $44.02M |
| P/E Ratio | 3.49 |
| EPS | $0.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.74 |
| Volume | 51 |
| Avg Volume | 0 |
| Revenue (TTM) | $35.09M |
| Net Income | $11.31M |
| Gross Margin | 0.00% |
2 analysts cover ATNM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $3.50.